OTC:RNAZ.O 5 February 2026

TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics shares surged nearly 19% Thursday after the company filed an amended IND application for a Phase 2a trial of TTX-MC138 in colorectal cancer patients. Trading volume hit 11.5 million shares, up from 8,500 the previous day. The dose-expansion study, set to begin in early 2026, will enroll up to 45 patients with positive ctDNA markers. The trial will run with Quantum Leap Healthcare Collaborative on the PRE-I-SPY platform.

5 February 2026

Biotechnology·OTC:RNAZ.O

M&G Emerges as a Leading FTSE 100 Dividend Stock: Five Key Reasons
June 28, 2026, 5:41 AM EDT. M&G (LSE:MNG) has become one of the FTSE 100's top dividend stocks since its 2019 spin-off from Prudential, with annual dividend increases reflecting resilience and robust cash flows. Its dividend yield has averaged 6.3%, significantly outpacing the FTSE 100 average of 3-4%. The company's strong Solvency II capital ratio and a conservative cash-flow-to-payout ratio of 63% support a progressive and sustainable dividend policy. Despite competitive pressures from peers like Aviva and Legal & General, M&G's solid execution and brand strength underpin confidence in ongoing dividend growth. Investors are advised to consider these factors carefully before buying shares.

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026

LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 5:48 AM EDT M&G Emerges as a Leading FTSE 100 Dividend Stock: Five Key Reasons June 28, 2026, 5:41 AM EDT. M&G (LSE:MNG) has become one of the FTSE 100’s top dividend stocks since its 2019 spin-off from Prudential, with annual dividend increases reflecting resilience and robust cash flows. Its dividend yield has averaged 6.3%, significantly outpacing the FTSE 100 average of 3-4%. The company’s strong Solvency II capital ratio and a conservative cash-flow-to-payout ratio of 63% support a progressive and sustainable dividend policy. Despite competitive pressures from

Bank of America (NYSE:BAC) trades near highs as Fed stress test details leave investors watching payout schedule

28 June 2026

Bank of America (NYSE:BAC) closed at $57.88, down 0.53% after hitting a 52-week high, as investors await a July board decision on the next dividend following a Fed stress test showing commercial and industrial loans make up the largest share of projected losses, keeping focus on corporate credit ahead of July 14 earnings.

PepsiCo (NASDAQ:PEP) starts holiday week as target cuts hit defensive trade

28 June 2026

PepsiCo (NASDAQ:PEP) jumped 1.34% to $141.39 Friday but remains 17.55% below its February high as Jefferies, BofA, and Citi slashed price targets ahead of July 9 Q2 results, signaling caution even as the average analyst target sits 18.27% above the last close.

Constellation Energy (NASDAQ:CEG) closes week close to 52-week low, as nuclear renewal initiative continues

28 June 2026

Constellation Energy (CEG) shares plunged 4.2% last week, erasing $4.1 billion in value and closing near a 52-week low at $264.02, even as the company filed for New York nuclear license extensions and secured Walmart’s first nuclear power purchase agreement, with Wall Street’s average analyst target still at $362.35.

OTC:RNAZ.O 5 February 2026

TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

Stock Market Today

Latest articles

US Stock Market Today: Live Updates 28.06.2026

Bank of America (NYSE:BAC) trades near highs as Fed stress test details leave investors watching payout schedule

PepsiCo (NASDAQ:PEP) starts holiday week as target cuts hit defensive trade

Constellation Energy (NASDAQ:CEG) closes week close to 52-week low, as nuclear renewal initiative continues

Latest Video